EQRx Announces Partnership Agreement with Abdul Latif Jameel Health to Commercialize Lead Oncology Programs in Middle East, Turkey and Africa
Retrieved on:
Monday, November 22, 2021
Oncology, Health, General Health, Research, Science, Pharmaceutical, Biotechnology, 1World, International Agency for Research on Cancer, NSCLC, Lung cancer, Esophageal cancer, TKI, Form, NMPA, APOLLO, New Drug Application, Prospectus, Risk, National Medical Products Administration, LinkedIn, Jameel, PD-L1, Organic, SEC filing, Social media, Catalog, Stomach, Failure, Method, Research, Sale, PIPE, Forward-looking statement, Large-cell lung carcinoma, Xi, Immunoglobulin G, Progression-free survival, Twitter, FDA, Ix, Growth, Securities Act of 1933, Patient, Adoption, Technology, Toxic Substances Control Act of 1976, Madison Avenue, EGFR, SEC, Proxy, Communication, Instagram, Antibody, III, Name, Disease, Pharmaceutical industry, Book, Lung Cancer, Aumolertinib, Sugemalimab, EQRx, LUNG CANCER, AUMOLERTINIB, SUGEMALIMAB, EQRX
Through the agreement, Abdul Latif Jameel Health will become EQRxs regulatory and commercial partner for aumolertinib and sugemalimab, if approved, in selected markets throughout the Middle East region, as well as in Turkey and all of Africa.
Key Points:
- Through the agreement, Abdul Latif Jameel Health will become EQRxs regulatory and commercial partner for aumolertinib and sugemalimab, if approved, in selected markets throughout the Middle East region, as well as in Turkey and all of Africa.
- Its our joint mission with EQRx to change that, a mission that is aligned with the values of the Jameel Family.
- Aumolertinib is a novel, irreversible EGFR-TKI that selectively inhibits both EGFR sensitizing and resistance mutations with high selectivity over wild-type EGFR.
- EQRx and Remaking Medicine are trademarks of EQRx, Inc.
1World Health Organization, International Agency for Research on Cancer.